How does a new drug behave in a damaged liver?
NCT ID NCT07025551
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed Phase 1 study looked at how the drug MK-8527 moves through the body in people with mild or moderate liver impairment compared to healthy volunteers. Researchers measured drug levels in the blood over time to understand how liver function affects the drug. The study enrolled 18 participants and also tracked any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MK-8527
- What this could lead to
- If successful, this study could help determine safe dosing of MK-8527 for people with liver problems.
- What could go wrong
- This is a very early, small study (18 people) focused on drug levels, not treatment effects. Results may not apply to broader populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arizona Clinical Trials ( Site 0001)
Chandler, Arizona, 85225, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates